<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039195</url>
  </required_header>
  <id_info>
    <org_study_id>01-142</org_study_id>
    <secondary_id>MSKCC-01142</secondary_id>
    <secondary_id>NCI-G02-2069</secondary_id>
    <nct_id>NCT00039195</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma</brief_title>
  <official_title>Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index II or III Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells&#xD;
      and either kill them or deliver cancer-killing substances to them without harming normal&#xD;
      cells. Combining chemotherapy with monoclonal antibody therapy, total-body irradiation, and&#xD;
      peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy&#xD;
      drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving chemotherapy with rituximab followed&#xD;
      by combination chemotherapy with or without rituximab, total-body irradiation, and peripheral&#xD;
      stem cell transplant works in treating patients with lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are stratified according to risk (low-intermediate vs high-intermediate or&#xD;
      high).&#xD;
&#xD;
      Patients receive induction chemotherapy comprising cyclophosphamide IV, doxorubicin IV over&#xD;
      15 minutes, and vincristine IV over 1-2 minutes on day 1; oral prednisone once daily on days&#xD;
      1-5; and filgrastim (G-CSF) subcutaneously (SC) once daily on days 7-11 or PEG-filgrastim&#xD;
      once at least 24 hours after infusion. Patients also receive rituximab IV 2-3 days apart for&#xD;
      a total of 2 doses during the week prior to the first course of chemotherapy and on day 1 of&#xD;
      courses 2-4 of chemotherapy. Treatment repeats every 14 days for a total of 4 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After the completion of induction chemotherapy, patients undergo CT scan and positron&#xD;
      emission tomography (PET) scanning. If the PET scan is positive in one or more nodal sites, a&#xD;
      repeat biopsy is performed. Patients with a negative PET scan OR a negative repeat biopsy&#xD;
      (including no evidence of lymphoma on repeat bone marrow biopsy) are assigned to receive&#xD;
      regimen A for consolidation therapy. Patients with a positive repeat biopsy are assigned to&#xD;
      receive regimen B for consolidation therapy.&#xD;
&#xD;
        -  Regimen A: Patients receive consolidation chemotherapy comprising etoposide IV over 1&#xD;
           hour on days 1-3, ifosfamide IV continuously over 24 hours on day 2, carboplatin IV on&#xD;
           day 2, and G-CSF SC once daily on days 5-12 or PEG-filgrastim once at least 24 hours&#xD;
           after infusion. Treatment repeats every 14 days for a total of 3 courses in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Regimen B: Patients receive consolidation chemotherapy as in regimen A for 3 courses.&#xD;
           Patients also receive rituximab IV on days -3 to -1 of course 3 of chemotherapy.&#xD;
           Patients undergo leukapheresis at the completion of course 3 (G-CSF continues from day 5&#xD;
           until the end of leukapheresis). After completion of leukapheresis, patients begin a&#xD;
           regimen of high-dose chemoradiotherapy comprising either total body irradiation twice&#xD;
           daily on days -10 to -7 and ifosfamide IV over 1 hour and etoposide IV continuously on&#xD;
           days -6 to -2 or BEAM chemotherapy comprising carmustine, etoposide, cytarabine, and&#xD;
           melphalan. Autologous peripheral blood stem cells (APBSC) are reinfused on day 0.&#xD;
           Patients also receive G-CSF SC daily beginning on day 5 and continuing until blood&#xD;
           counts recover. Beginning on day 42 post-APBSC, if blood counts have recovered, patients&#xD;
           receive rituximab IV once weekly for 4 weeks. Rituximab is repeated beginning on day 180&#xD;
           in the absence of disease progression.&#xD;
&#xD;
      Patients who receive consolidation therapy on regimen A are followed at 4-6 weeks after&#xD;
      chemotherapy and patients who receive consolidation therapy on regimen B are followed at&#xD;
      90-120 days after transplantation. All patients are followed closely for 5 years and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40-98 patients will be accrued for this study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Kaplan-Meier estimates will be used to verify the progression free survival.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed aggressive diffuse large B-cell lymphoma&#xD;
&#xD;
          -  CD20-positive disease&#xD;
&#xD;
          -  Age-adjusted International Prognostic Index II or III defined by the presence of at&#xD;
             least 1 of the following:&#xD;
&#xD;
               -  Karnofsky performance status 10-70%&#xD;
&#xD;
               -  Lactate dehydrogenase greater than 200 U/L&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  Positron emission tomography avid measurable disease&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 64&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 50,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease or pattern&#xD;
             consistent with Gilbert's disease&#xD;
&#xD;
          -  Hepatitis B surface antigen and hepatitis C antibody negative&#xD;
&#xD;
          -  No chronic, active, or persistent hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No chronic renal insufficiency&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 50% by echocardiogram or MUGA scan&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No cardiac arrhythmias except chronic atrial fibrillation&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other medical illness that would preclude study&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior biologic therapy for malignancy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for malignancy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior steroids allowed if received no more than 1 week of therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for malignancy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior surgery for malignancy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior therapy for malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Moskowitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>December 15, 2015</results_first_submitted>
  <results_first_submitted_qc>June 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2016</results_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Induction R-CHOPac Therapy</title>
          <description>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Induction R-CHOPac Therapy</title>
          <description>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Kaplan-Meier estimates will be used to verify the progression free survival.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Induction R-CHOPac Therapy</title>
            <description>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Kaplan-Meier estimates will be used to verify the progression free survival.</description>
          <units>percentage of patients progression free</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="69" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Induction R-CHOPac Therapy</title>
          <description>Induction R-CHOPac Therapy for patients with B-Cell Lymphoma</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hemorrhage, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Supravent arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>GI, other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Ileus (or neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pain - Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Radiation mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Delusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" events="89" subjects_affected="89" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="94" subjects_affected="94" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="64" subjects_affected="64" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="70" subjects_affected="70" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="79" subjects_affected="79" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Craig Moskowitz</name_or_title>
      <organization>Memorial Slaon Kettering</organization>
      <phone>212-639-7992</phone>
      <email>moskowic@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

